Betta Pharmaceuticals Co., Ltd.

Other

Beta Pharma, Inc.

Beijing Betta Pharmaceuticals Co., Ltd

Fujian Haixi Pharmaceuticals, Inc.

Betta Pharmacueticals Co., Ltd.

Kang, Xinshan

Fenlai Tan

Wei Long

Yinxiang Wang

Yunyan Hu

Yanping Wang

Cunbo Ma

Lieming Ding

Hong Cao

Shaojing Hu

Xinshan Kang

Xiaoyan Shen

Wei He

Fei Wang

Yong Liu

Don Zhang

Bin Han

Guojian Xie

Charles Davis

Xiangdong Zhao

Haima Ai

Liufeng Zhou

Haima Al

The present invention relates to novel analogs of glucagon like peptide and compositions that are useful for up-regulating insulin expression in mammals and for treating diabetes. In particular, these peptide derivatives have a peptide mimic linker and provides long duration of action for the treatment of diabetes and other insulinotropic peptide related diseases, gastrointestinal function and activities associated with glucagon levels.

Glucagon like peptide analogs, composition, and method of use

The compound of Formula (I), pharmaceutically acceptable salts thereof, solvates thereof, chelates thereof, non-covalent complexes thereof or produgs of compounds mentioned above or the mixture of any form above mentioned are provided. The use of the compounds in manufacturing a medicament for the treatment and/or prevention of diabetes, obesity and related disorders. 

Compound for increasing kinase active and application thereof

The invention relates to 4-[(3-ethynylphenyl)amino]-6,7-benzo-12-crown-quinazoline hydrochloride, its new crystalline forms, its therapeutic usage for treatment of diseases mediated by EGFR kinase and its combinatory therapeutic usage together with other therapeutic agents. The invention also provides synthetic methods for preparation of 4-[(3-ethynylphenyl)amino]-6,7-benzo-12-crown-quinazoline hydrochloride, its new crystalline forms, and the relevant synthetic intermediates for synthesis of 4-[(3-ethynylphenyl)amino]-6,7-benzo-12-crown-quinazoline hydrochloride.

Icotinib hydrochloride, synthesis, crystalline forms, pharmaceutical compositions, and uses thereof

This invention relates to certain novel fused quinazoline derivatives (Formula I) as c-Met inhibitors which is shown as formula I, their synthesis and their use for treating a c-Met mediated disorder. More particularly, this invention is directed to fused heterocyclic derivatives useful inhibitors of c-Met, methods for producing such compounds and methods for treating as c-Met mediated disorder 

Substituted fused heterocycles as c-Met tyrosine kinase inhibitors

The polymorphic forms of the compound of Formula I, the preparation thereof including the preparation of the intermediates, the pharmaceutical compositions thereof and the uses of a polymorph above in the manufacture of medicaments for treating a disease, a disorder or a condition are disclosed. 

Stable polymorphic forms of compound as hypoxia mimetics, and uses thereof

Provided is a glucagon-like peptide-1 (GLP-1) analog shown as the following formula, wherein X is selected from glycine and glycinamide. The GLP-1 analog has a non-proteogenic amino acid residue in position 8 relative to the sequence GLP-1, and is acylated with a moiety comprising two acidic groups to the lysine residue in position 26. The GLP-1 analog is resistant to dipeptidyl peptidase IV so as to have an extended half-life in vivo. Also provided is a use of the GLP-1 analog in conquering blood sugar. 

Glucagon-like peptide-1 analogues and uses thereof

This invention relates to new compounds that can serve as hypoxia mimetics. This invention also relates to methods of increasing HIF levels or activity in a subject or treating a condition associated with HIF levels or activity in a subject by administering to the subject at least one of these compounds.

Compounds as hypoxia mimetics, and compositions and uses thereof

Growing community of inventors

Beijing, China

Fenlai Tan